Document is current
Any future updates will be listed below
-
Authors
Bilusic, Marijo https://orcid.org/0000-0003-1020-689X
Gannamedi, Durga Prasad
Challu, Bhipasha https://orcid.org/0009-0001-2787-1303
Ferdous, Shomita
Mateo-Victoriano, Beatriz https://orcid.org/0000-0003-3281-4933
Pokharel, Sheela
Bayik, Defne https://orcid.org/0000-0002-4740-8869
Sharma, Janaki https://orcid.org/0000-0001-7177-4319
Lombard, David B https://orcid.org/0000-0002-4292-0185
Rai, Priyamvada https://orcid.org/0000-0001-7822-7553
-
Funding
Funding for this research was provided by:
HHS | NIH | National Cancer Institute (R01CA254100)
HHS | NIH | National Cancer Institute (R01CA253986)
HHS | NIH | National Cancer Institute (P30CA240139)
HHS | NIH | National Institute on Aging (R33AG077856)
U.S. Department of Defense (ME200030)
Melanoma Research Alliance (1434401)
Florida Department of Health (24B12)
U.S. Department of Veterans Affairs (I01BX006593)
- License Information
-
More Information
Article History
Received: 1 August 2025
Revised: 26 February 2026
Accepted: 3 March 2026
First Online: 6 April 2026
Disclosure and competing interests statement
: M Bilusic has received research support via his institution from Surface Oncology; Merck Sharp & Dohme; Eli Lilly & Co; Hookipa Pharma; Marengo Therapeutics and Bicycle Therapeutics. The remaining authors declare no competing interests.
